Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
OrforglipronSmall moleculeNo amino acid sequence. Icon reflects category theme only.Also known as: LY3502970, OWL-833, Foundayo
FDA approval came 50 days after Eli Lilly filed the application. That speed tells you something about the demand for a GLP-1 drug you can swallow. Orforglipron (brand name Foundayo) is the first oral non-peptide GLP-1 receptor agonist to reach the market. It isn't actually a peptide; it's a small molecule that survives stomach acid on its own, no enteric coating or fasting window required. In the ATTAIN-1 trial, 3,127 adults averaged 12.4% body weight loss at 72 weeks on the highest dose. GI side effects run higher than injectable options, and discontinuation rates reflect that trade-off. Self-pay pricing starts at $149 for the first month through LillyDirect.
Orforglipron (Foundayo, CAS 2172908-40-4, molecular formula C48H48F2N10O5, MW 883 Da) is a synthetic small molecule GLP-1 receptor agonist, not a peptide. Eli Lilly developed it under the research codes LY3502970 and OWL-833. It's the first oral GLP-1 drug that requires no fasting window and no absorption enhancer. The drug binds within the transmembrane core of the GLP-1 receptor at a different site than semaglutide or native GLP-1. This allosteric mechanism triggers the same downstream cascade: insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction through hypothalamic signaling. Oral bioavailability sits around 79%, and there are zero fasting or water restrictions. Take it any time of day with or without food. In ATTAIN-1 (n=3,127, 72 weeks)[1], participants on the 17.2 mg dose lost an average of 27.3 lbs, or 12.4% of body weight. Placebo lost 2.2 lbs. The head-to-head ACHIEVE-3 trial found orforglipron 36 mg beat oral semaglutide 14 mg for both HbA1c reduction and weight loss. ATTAIN-4 confirmed that patients switching from injectable GLP-1s maintained their weight loss on oral orforglipron. The FDA approved Foundayo on April 1, 2026 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. GI discontinuation rates ran about 4x higher than oral semaglutide in trials. No cardiovascular outcomes data exists yet; a CVOT is ongoing. Real-world community data is nonexistent because the drug only launched on April 6, 2026.
Most GLP-1 drugs are peptides that mimic the gut hormone GLP-1 by binding to the same pocket on the receptor's surface. Orforglipron does something different. At 883 daltons, it's a fraction of the size of semaglutide (4,114 Da) and binds inside the receptor's transmembrane domain rather than the extracellular orthosteric pocket. Specifically, it contacts transmembrane helices 1, 2, 3, and 7 along with extracellular loop 2 (ECL2). This allosteric binding stabilizes the receptor in an active conformation that preferentially activates Gs-protein signaling. The downstream result is identical to what injectable GLP-1 drugs produce: glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, slowed gastric emptying, and reduced appetite via hypothalamic and brainstem GLP-1 receptors. The small-molecule scaffold makes orforglipron resistant to proteolytic degradation in the GI tract. Stomach acid and digestive enzymes break down peptide-based GLP-1 agonists within minutes; orforglipron passes through intact. Oral bioavailability reaches approximately 79% without any absorption enhancers or food restrictions. Hepatic CYP3A4 handles primary metabolism. Terminal half-life ranges from 29 to 68 hours depending on dose and treatment duration (Pratt et al.)[2], which supports once-daily dosing. Peak plasma concentration arrives 2 to 4 hours after swallowing the tablet.
FDA-approved oral non-peptide GLP-1 agonist. Phase 3 shows 11.1–12.4% body weight loss (ITT/completers) at highest dose over 72 weeks. Superior to oral semaglutide 14mg for both HbA1c reduction and weight loss in head-to-head ACHIEVE-3. GI discontinuation rate (~3.5–10%) higher than injectables.
ATTAIN-1 (Phase 3, n=2,400, 72 weeks, NEJM 2025, PMID 40960239); ACHIEVE-3 (Phase 3 head-to-head vs. oral semaglutide, Lancet 2026)
Only 72-week Phase 3 data available; no cardiovascular outcomes trial results yet (CVOT ongoing); higher GI AE rate than injectables; T2D indication not yet FDA-approved in US; zero post-market real-world data (launched April 6, 2026)
No community data yet: drug launched April 6, 2026. Check r/Semaglutide and r/WeightLossAdvice in 4–8 weeks.
Drug launched April 6, 2026: no real-world community experience exists. Alignment status will shift to "aligned" or "partially-aligned" as user reports accumulate. Revisit in 60–90 days.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.8mg | Daily |
| Moderate | 5.5mg | Daily |
| Aggressive | 17.2mg | Daily |
Oral tablet. No vials, no syringes, no reconstitution math. That alone makes orforglipron the simplest GLP-1 drug to start. Titration schedule matters more than most beginners realize. You start at 0.8 mg daily for a full 30 days before moving to 2.5 mg. Then 5.5 mg for another 30 days. After that, you can escalate to 9 mg, 14.5 mg, or 17.2 mg based on how your body responds. Skipping steps or rushing the schedule significantly increases nausea and GI side effects. The detail that catches people off guard: if you miss 7 or more consecutive doses, you restart the entire titration from 0.8 mg. Not from where you left off. Swallow the tablet whole. Don't crush, break, or chew it. Take it any time of day, food or no food, water or no water. No awkward 30-minute fasting window like Rybelsus. Constipation hits harder than most expect (30% in trials). Start extra fiber and fluids on day 1, not after symptoms appear. Each dose escalation step tends to bring a fresh wave of nausea for 5 to 7 days; plan increases during low-stress weeks.
Intended for continuous long-term use. Weight regain expected after stopping: same as other GLP-1 drugs. If you miss 7 or more consecutive days, restart the titration schedule.
Continuous indefinite use is per FDA label design: weight regain is rapid and substantial on discontinuation (same as injectable GLP-1 drugs). No receptor desensitization, antibody formation, or hormonal axis suppression concerns apply to this small molecule. Cycling is not medically recommended.
Or use the universal Peptide Calculator for any peptide.
Expected: 11.1–12.4% mean body weight loss at 72 weeks (Phase 3, ITT/completers); ~59% of patients achieve ≥10% weight loss at the highest dose (ATTAIN-1 efficacy estimand)
Monitor: Monitor renal function during GI-heavy titration steps (AKI risk from dehydration). Check heart rate periodically (orforglipron increases HR more than oral semaglutide). Oral contraceptive users: switch to non-oral method or use barrier contraception for 30 days after initiation and each dose escalation.
Morning, evening, or midday all work fine.
Swallow it whole with whatever amount of water you prefer. No crushing, breaking, or chewing.
You can take it on an empty stomach, with a meal, or with a snack. No restrictions.
Follow the titration schedule exactly: 0.8 mg daily for 30 days, then 2.5 mg for 30 days, then 5.5 mg for 30 days, then your provider will move you to 9 mg, 14.5 mg, or 17.2 mg.
Don't double up.
If you miss 7 or more consecutive days, restart from 0.8 mg and work through the full titration again.
Store tablets at room temperature, 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). Excursions to 15 to 30 degrees Celsius are fine.
This is a standard oral medication.
No alternative routes studied or available
Unlike oral semaglutide, no fasting or water volume restrictions. Swallow tablet whole only.
Used as background therapy in ACHIEVE-3 T2D population; complementary glycemic mechanism (insulin sensitizer + GLP-1 agonist). No interaction concerns.
Continue existing metformin dose; no adjustment required unless hypoglycemia occurs
Concurrent use of two GLP-1 receptor agonists is contraindicated per FDA label: doubled GI AE risk, no additive efficacy demonstrated
Do not combineDual GIP/GLP-1 agonist: concurrent GLP-1 agonism contraindicated; no safety data for combination
Do not combineGLP-1 receptor agonist: concurrent use with another GLP-1 agonist is contraindicated per FDA label
Do not combineTriple GIP/GLP-1/glucagon agonist: includes GLP-1 agonism; concurrent use is contraindicated
Do not combinePricing updated 2026-04-09
The black box warning comes first: orforglipron carries a medullary thyroid carcinoma (MTC) risk based on animal data. Thyroid C-cell tumors developed in rodent studies at clinically relevant exposures. No confirmed human cases exist, but the GLP-1 class label applies. Anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not take this drug. Pancreatitis is the second concern. Cases were reported in clinical trials. Severe, persistent abdominal pain radiating to the back warrants immediate medical evaluation and discontinuation. GI side effects are the daily reality for most users during dose escalation. Nausea is the most common complaint, followed by constipation (reported at 30% incidence in Phase 3, higher than most GLP-1 drugs), diarrhea, vomiting, and dyspepsia. Abdominal pain, burping, heartburn, and gas round out the GI profile. Discontinuation due to GI adverse events ran approximately 3.5 to 10% across dose groups; that rate was about 4x higher than oral semaglutide in the ACHIEVE-3 comparison. Direct contact between the oral tablet and the stomach lining probably explains the higher GI burden compared to injectable delivery. Headache, fatigue, and hair loss appear in the trial data. Heart rate elevation is more prominent with orforglipron than with oral semaglutide, based on ACHIEVE-3 monitoring. Resting heart rate should be checked at baseline and at each dose escalation. Acute kidney injury is possible during severe GI episodes. Dehydration from vomiting or diarrhea can drop renal perfusion quickly. Renal function monitoring during GI-heavy titration steps is recommended. Gallbladder disease (cholelithiasis, cholecystitis) carries the same class-level association seen with other GLP-1 drugs. Oral hormonal contraceptives may lose effectiveness during initiation and each dose escalation. Gastric emptying delay alters absorption timing. The label recommends switching to a non-oral contraceptive method or adding barrier contraception for 30 days after starting and after each dose increase. Stop orforglipron and contact a provider if you notice a neck mass, persistent hoarseness, difficulty swallowing, severe abdominal pain that doesn't resolve, or signs of a serious allergic reaction. Pregnancy is a contraindication; discontinue immediately if pregnancy occurs. Women of reproductive potential should use reliable contraception during treatment.
Verify Orforglipron dosing and safety with a second opinion
Orforglipron is a synthetic small molecule: it cannot be replicated by compounding pharmacies and is not on the FDA drug shortage list. No gray market supply exists. All supply flows through licensed US pharmacies, LillyDirect, or telehealth platforms. Counterfeit risk is essentially zero in the current early-access market.
| Test | When | Target |
|---|---|---|
| Renal function (eGFR, serum creatinine) | Baseline; repeat during GI-heavy escalation phases if nausea/vomiting/diarrhea is significant | eGFR >60 mL/min/1.73m² preferred; no dose adjustment per label for renal impairment, but monitor closely |
| Heart rate (resting) | Baseline; each dose escalation visit | Clinically significant if >10 bpm sustained elevation above baseline; evaluate if symptomatic tachycardia |
| HbA1c | Baseline; every 3 months in T2D patients | <7.0% (T2D standard); <5.7% (normoglycemia threshold) |
| Body weight | Monthly | Expect ~2–5% loss by week 12; ~10–12% by week 72 at maximum dose |
| Liver enzymes (ALT, AST) | Baseline; periodically if symptomatic | — |
| Fasting lipid panel (triglycerides, non-HDL, total cholesterol) | Baseline; 12–24 weeks after reaching maintenance dose | — |
| Systolic blood pressure | Baseline; every 3 months | — |
Acute kidney injury risk from volume depletion secondary to GI adverse events
Orforglipron increases resting HR more than oral semaglutide (ACHIEVE-3 data)
Glycemic response; dose titration decisions; hypoglycemia risk with co-medications (insulin/sulfonylureas)
Primary efficacy metric; informs dose escalation vs. maintenance decision
Orforglipron is primarily cleared via hepatic CYP3A4 metabolism
ATTAIN-1 showed significant triglyceride and non-HDL cholesterol reductions; confirms metabolic benefit
ATTAIN-1 showed meaningful SBP reductions; also monitors for dehydration during GI-active periods
Starting dose 0.8mg. Mild appetite suppression begins. GI side effects (nausea, stomach discomfort) most likely during this period. Minimal weight change expected.
Titrating through 2.5mg and 5.5mg. Appetite reduction becomes more noticeable. Early weight loss of 2-4% body weight. Nausea typically fades as each dose level stabilizes.
Reaching maintenance doses (9-17.2mg). Steady weight loss averaging 0.5-1 lb/week. Measurable improvements in waist circumference and metabolic labs.
Weight loss approaches 10-12% average at the highest dose based on ATTAIN-1 data. Triglycerides, non-HDL cholesterol, and blood pressure improve. Rate of loss slows as new equilibrium is reached.
Weeks 1 through 4 (0.8 mg): The starting dose is sub-therapeutic by design. Don't expect meaningful weight change yet. GI side effects, especially nausea and stomach discomfort, are most likely during week 1. Occasional vomiting can happen. The purpose of this phase is purely GI adaptation. No community experience exists to draw from; the drug launched April 6, 2026. Weeks 5 through 12 (2.5 to 5.5 mg): Appetite suppression becomes noticeable as the dose climbs. Early weight loss in the range of 2 to 4% of body weight is typical based on Phase 3 dose-response data. Nausea tends to fade 5 to 7 days after each dose step; constipation and diarrhea are reported at these levels. Weeks 13 through 20 (9 to 14.5 mg): This is the entry into maintenance territory. Weight loss steadies at roughly 0.5 to 1 lb per week. Waist circumference, triglycerides, non-HDL cholesterol, and systolic blood pressure begin to show measurable improvements. ATTAIN-1 data showed that up to 91% of prediabetic participants reached near-normal blood glucose by this phase. GI events are generally tolerable for patients who titrated slowly. Some trial participants reported hair loss starting around this point. Weeks 21 through 72 (17.2 mg): Weight loss approaches the 11 to 12% average reduction seen in ATTAIN-1 (ITT analysis), or 12.4% among completers. The rate of loss slows as the body reaches a new equilibrium. Metabolic lab values continue to improve. Heart rate elevation is more prominent at this dose than with oral semaglutide per ACHIEVE-3 data. Constipation and alopecia were reported in trial subsets at this stage.
Sub-therapeutic dose: minimal weight change expected. GI side effects (nausea, stomach discomfort) are most common during initiation week.
No data yet: drug launched April 6, 2026.
Appetite suppression becomes noticeable. Early weight loss ~2–4% based on dose-response data. GI effects generally improve as each dose level stabilizes.
No data yet.
Steady weight loss averaging 0.5–1 lb/week. Measurable improvements in waist circumference, triglycerides, non-HDL cholesterol, systolic BP. Prediabetic patients: up to 91% achieve near-normal blood glucose (ATTAIN-1).
No data yet.
Weight loss plateau approaching 11–12% mean reduction (ITT) or 12.4% (completers). Rate of loss slows as new set point is reached. Metabolic labs continue improving.
No data yet.
Source: Pratt et al. Phase 1a (PMID 37344954); steady-state t½ 48-68h across dose range
Loading the interactive decay curve.
Orforglipron (Foundayo) received FDA approval on April 1, 2026 for chronic weight management in adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity. It was the fifth drug approved under the FDA's National Priority Voucher program. Orforglipron is not currently approved for type 2 diabetes in the United States, though Phase 3 data from ATTAIN-2 supports that indication and Eli Lilly is expected to pursue it. Orforglipron is a patented small molecule manufactured exclusively by Eli Lilly. No generic versions exist. It cannot be legally compounded because it is not a peptide and is not on the FDA drug shortage list. Any product sold as "compounded orforglipron" is fraudulent. Obtain it only through licensed US pharmacies, LillyDirect, or verified telehealth platforms. WADA status has not been determined for orforglipron specifically, though GLP-1 receptor agonists are not currently prohibited in competition. This content is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any medication.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
